Metabolic agents in the management of diabetic coronary patients: A new era

International Journal of Cardiology

Volumn 127, Issue 1, 2008, Pages 124-125

  Marazzi, Giuseppe ^a   Volterrani, Maurizio ^a   Rosano, Giuseppe M C ^a  

^a Cardiovascular Research Unit   (Italy)

Author keywords

Coronary artery disease; Diabetes; Metabolic agents

Indexed keywords

DICHLOROACETIC ACID; ESSENTIAL AMINO ACID; ETOMOXIR; INSULIN SENSITIZING AGENT; PERHEXILINE; RANOLAZINE; TRIMETAZIDINE;

ARTICLE; CITRIC ACID CYCLE; CORONARY ARTERY DISEASE; DIABETIC PATIENT; FATTY ACID OXIDATION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; INSULIN RESISTANCE; PRIORITY JOURNAL;

ACETANILIDES; CITRIC ACID CYCLE; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DICHLOROACETATE; ENZYME INHIBITORS; EPOXY COMPOUNDS; HUMANS; INSULIN RESISTANCE; PERHEXILINE; PIPERAZINES; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 43949094514     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.10.042     Document Type: Article

References (9)

1. Celik T., Kursakliogu H., Iyisoy A., and Jata B. Metabolic agents in the management of diabetic coronary patients: A new era. Int J Cardiol 127 (2008) 133-134
2. MacInnes A., Fairman D.A., Binding P., et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Resp 93 (2003) E26-E32
3. Antzelevitch C., Belardinelli L., Zygmunt A., et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110 (2004) 904-910
4. Undrovinas A.L., Undrovinas N.A., Belardinelli L., et al. Ranolazine inhibits late sodium current in isolated left ventricular myocytes of dogs with heart failure. J Am Coll Cardiol 43 Suppl. 1 (2004) A178
5. Chaitman B.R., Skettino S.L., Parker J.O., et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 43 (2004) 1375-1382
6. Chaitman B.R., Pepine C.J., Parker J.O., et al. Effects of ranolazine with atenol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 291 (2004) 309-316
7. Szwed H., Pachocki R., Domzal-Bochenska M., et al. Efficacy and tolerance of trimetazidine, a metabolic antianginal, in combination with a hemodynamic antianginal in stable exertion angina. TRIMPOL I, a multicenter study -- Presse Med. vol. 29 (10) (Mar 18 2000) 533-538
8. Ruzyllo W., Szwed H., Sadowski Z., et al. Efficacy of trimetazidine in patients with recurrent angina: a subgroup analysis of the TRIMPOL II study. Curr Med Res Opin 20 9 (Sep 2004) 1447-1454
9. Sudre Y., Becq-Giraudon B., Pouget-Abadie J.F., Demange J., and Boutaud P. Hypoglycemic complications in the course of treatment with perhexilline maleate and beta-blocking agents. Coeur Med Interne 16 2 (Apr-Jun 1977) 279-284